Caracterización de las potenciales interacciones fármaco-fármaco en pacientes hospitalizados en una unidad de cuidados intensivos de un hospital de tercer nivel.

44 Páginas incluye diagramas

Autores:: Hernández Londoño, Marcela

Tipo de recurso:

Fecha de publicación:: 2015

Institución:: Universidad de la Sabana

Repositorio:: Repositorio Universidad de la Sabana

Idioma:: spa

id	REPOUSABA2_fe727a14e279df802adc8b03326f86d8
oai_identifier_str	oai:intellectum.unisabana.edu.co:10818/17940
network_acronym_str	REPOUSABA2
network_name_str	Repositorio Universidad de la Sabana
repository_id_str
dc.title.es_CO.fl_str_mv	Caracterización de las potenciales interacciones fármaco-fármaco en pacientes hospitalizados en una unidad de cuidados intensivos de un hospital de tercer nivel.
title	Caracterización de las potenciales interacciones fármaco-fármaco en pacientes hospitalizados en una unidad de cuidados intensivos de un hospital de tercer nivel.
spellingShingle	Caracterización de las potenciales interacciones fármaco-fármaco en pacientes hospitalizados en una unidad de cuidados intensivos de un hospital de tercer nivel. Medicamentos -- Colombia Administración -- Cuidados intensivos Atención médica
title_short	Caracterización de las potenciales interacciones fármaco-fármaco en pacientes hospitalizados en una unidad de cuidados intensivos de un hospital de tercer nivel.
title_full	Caracterización de las potenciales interacciones fármaco-fármaco en pacientes hospitalizados en una unidad de cuidados intensivos de un hospital de tercer nivel.
title_fullStr	Caracterización de las potenciales interacciones fármaco-fármaco en pacientes hospitalizados en una unidad de cuidados intensivos de un hospital de tercer nivel.
title_full_unstemmed	Caracterización de las potenciales interacciones fármaco-fármaco en pacientes hospitalizados en una unidad de cuidados intensivos de un hospital de tercer nivel.
title_sort	Caracterización de las potenciales interacciones fármaco-fármaco en pacientes hospitalizados en una unidad de cuidados intensivos de un hospital de tercer nivel.
dc.creator.fl_str_mv	Hernández Londoño, Marcela
dc.contributor.advisor.none.fl_str_mv	Bustamante Rojas, Carlos Eduardo Tribiño, Gabriel
dc.contributor.author.none.fl_str_mv	Hernández Londoño, Marcela
dc.subject.none.fl_str_mv	Medicamentos -- Colombia Administración -- Cuidados intensivos Atención médica
topic	Medicamentos -- Colombia Administración -- Cuidados intensivos Atención médica
description	44 Páginas incluye diagramas
publishDate	2015
dc.date.accessioned.none.fl_str_mv	2015-08-27T16:41:37Z
dc.date.available.none.fl_str_mv	2015-08-27T16:41:37Z 2015-08-21
dc.date.copyright.none.fl_str_mv	2015-08-21
dc.date.created.none.fl_str_mv	2015
dc.date.issued.none.fl_str_mv	2015-08-27
dc.type.es_CO.fl_str_mv	bachelorThesis
dc.type.coarversion.fl_str_mv	http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv	http://purl.org/coar/resource_type/c_7a1f
dc.type.local.none.fl_str_mv	Tesis de especialización
dc.type.hasVersion.es_CO.fl_str_mv	publishedVersion
dc.identifier.citation.none.fl_str_mv	Rhanna Emanuela Fontenele Lima de Carvalho, Adriano Max Moreira Reis, Leila Márcia Pereira de Faria, Karine Santana de Azevedo Zago, Silvia Helena De Bortoli Cassiani, Prevalence of drug interactions in intensive care units in Brazil, Acta Paul Enferm. 2013; 26(2):150-7. Martína M, Codinna C, Tuseta M, Carné X, Noguéc, S, Ribasa J. Problemas relacionados con la medicación como causa del ingreso hospitalario, Med Clin (Barc) 2002;118(6):205-10 Pirmohamed M., James S., Meakin S., Green C., Scout A., Walley T., Farrar K., Park K., Breckenridge A. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18.820 patients. BMJ 2004; 329:15-19 Pouyanne P., Haramburu F., Imbs J., Bégaud B. Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. BMJ 2000; 320: 1036 A. David Rodríguez, Drug- drug interactions, drugs and the pharmaceutical sciences, 2th Ed, Vol 179, (2008); p. 643-659 R. A. Caribé, G. R. Chaves, J. D. Pocognoni2 e I. A. Souza, Potenciales interacciones medicamentosas en pacientes con sepsis internados en la unidad de terapia intensiva, Farm Hosp. 2013;37(5):383-387 Rivkin A, Yin H. Evaluation of the role of the critical care pharmacist in identifying and avoiding or minimizing significant drug-drug interactions in medical intensive care patients. J Crit Care. 2011 Feb;26(1):104.e1-e6. Reis AM, De Bortoli Cassiani SH. Prevalence of potential drug interactions in patients in an intensive care unit of a university hospital in Brazil Clinics 2011; 66: 9–15. Plaza J, Álamo M, Torres P, Fuentes A, López F, Interacciones de medicamentos y eventos adversos en fármacos utilizados en una unidad de cuidados intensivos, Rev Med Chile 2010; 138: 452-460 Bergk V, Gasse C, Rothenbacher D, Loew M, Brenner H, Haefeli WE. Drug interactions in primary care: impact of a new algorithm on risk determination. Clin Pharmacol Ther 2004; 76: 85-96 Marjan Askari, Saied Eslami, Mathijs Louws, Peter C. Wierenga, Dave A. Dongelmans, Rob A. Kuiper and Ameen Abu-Hanna, Frequency and nature of drugdrug interactions in the intensive care unit, Pharmacoepidemiology and Drug Safety, 2013; 22: 430–437 Smithburger P, Kane-Gill SL, Seybert AL, Drug–drug interactions in the medical intensive care unit: an assessment of frequency, severity and the medications involved, International Journal of Pharmacy Practice 2012, 20, pp. 402–408 Committee on Quality of Health Care in America: Institute of Medicine. To erris human: building a safer health system. Washington, DC: National Academy Press; 2000 Silvana Maria de Almeida1, Cinthia Scatena Gama, Nelson Akamine, Prevalence and classification of drug-drug interactions in intensive care patients, Einstein. 2007; 5(4):347-351 E. Sona, M.L Gora, y S.L Roeder; Methods used by pharmacy departments to identify drugs interactions, Am. J Hosp. Pharm., 50, 2546 (1993) Grattagliano I, Portincasa P, D´Ambrosio G, Palmieri VO, Palaciano G. Avoiding drug interactions: here´s help. J Fam Pract 2010;59:322-9. Strand LM, Morley PC, Cipolle RJ, Ramsey R, Lamsam GD. Drug-related problems: their structure and function. Drug Intell Clin Pharm 1990; 24: 1093-7. Bucşa Camelia, Farcaş Andreea, Cazacu Irina, Leucuta Daniel, Achimas-Cadariu Andrei, Mogosan Cristina, Bojita Marius, How many potential drug–drug interactions cause adverse drug reactions in hospitalized patients?, European Journal of Internal Medicine 24 (2013) 27–33. Hammes J, Pfuetzenreiter F, da Silveira F, Koenig A, Adrieno Westphal G, Potential drug interactions prevalence in intensive care units Rev Bras Ter Intensiva. 2008; 20(4): 349-354 Becker et al, Hospitalizations and emergency department visits due to drug–drug interactions: a literature review, Pharmacoepidemiology and Drug Safety, 2007; 16: 641–651 Medscape Multispeciality, Identification and Management of Drug Interactions, Faculty and Disclosures. http://www.medscape.org/viewarticle/41837 J. Díaz, J. López, Descripción de las Interacciones fármaco-fármaco en los servicios de Medicina interna de tres hospitales de tercer nivel de Bogotá, Rev. Col. Cienc. Quím. Farm. 34 (2), 181-192, Vol. 34, No. 2, 2005. Joseph A. Khan A. A comparison of the Micromedex and Lexicomp medicine information databases, BHR Hospitals Sept 2004, http://www.ukmi.nhs.uk/filestore/misc/AcomparisonoftheMicromedexandLexicompDatabases.pdf Barrons R. Evaluation of personal digital assistant software for drug interactions. Am J Health Syst Pharm. 2004; 61(4):380-85. Roberts D, Richard H. Drug absorption, distribution, metabolism and excretion considerations in critically ill adults. Expert Opin, Drug Metab. Toxicol. (2013) 9(9). Hansten, P.D. Drug Interaction management. Pharm. World Sci 2003; 25 (3):94- 97, doi: 10.1023/A: 1024077018902. Doubova SV, Reyes-Morales H, del Pilar Torres-Arreola L, Suárez-Ortega M. Potential drug - drug and drug– disease interactions in prescriptions for ambulatory patients over 50 years of age in family medicine clinics in Mexico City. BMC Health Serv Res 2007; 7:147. Zhan C, Coreea de Araujo R, Bierman AS, Sangl J, Miller MR, Wickizer SW, et al. Suboptimal prescribing in elderly outpatients: potentially harmful drug –drug and drug – disease combinations. J Am Geriatr Soc 2005;53:262-7 Devlin JW, Roberts RJ. Pharmacology of commonly used analgesics and sedatives in the ICU: benzodiazepines, propofol, and opioids. Crit Care Clin. 2009;25:431-49, doi: 10.1016/j.ccc.2009.03.003 Riker RR, Fraser GL. Altering intensive care sedation paradigms to improve patient outcomes. Crit Care Clin. 2009; 25:527-38. Chweickert WD, Kress JP. Strategies to optimize analgesia and sedation. Crit Care. 2008; 12 Suppl 3:S6 Overholser BR, Foster DR. Opioid pharmacokinetic drug-drug interactions. Am J Manag Care. 2011 Sep; 17 Suppl 11:S276-87. Review. López M, Metabolismo de fármacos: Enzimas CYP3A (sub familia del citocromo P450), 20 mar. 2013 14:22 infofarmacia www.infofarmacia.com/bioquimica/metabolismo-de-farmacos-enzimas-cyp3a-sub-familia-delcitocromo-p450 Wolters Kluwer Health Lexicomp, comprehensive pharmacology information app. 2015 Cruciol-Souza JM, Thomson JC. Prevalence of potential drug-drug interactions and its associated factors in a Brazilian teaching hospital. J Pharm Pharm Sci. 2006; 9:427-33. Lima REF, Cassiani SHB. Potential drug interactions in intensive care patients at a teaching hospital. Rev Latinoam Enfermagem 2009 março-abril; 17(2):222-7. El Samia Mohamed SMA, Gad ZM, El-Nimr NA, Abdel Razek AAH (2013) Prevalence and Pattern of Potential Drug-Drug Interactions in the Critical Care Units of a Tertiary Hospital in Alexandria, Egypt. Adv Pharmacoepidemiol Drug Saf 2: 144. Strand LM, Morley PC, Cipolle RJ, Ramsey R, Lamsam GD. Drug-related problems: their structure and function. Drug Intell Clin Pharm 1990; 24: 1093-7.
dc.identifier.uri.none.fl_str_mv	http://hdl.handle.net/10818/17940
dc.identifier.local.none.fl_str_mv	261219 TE07725
identifier_str_mv	Rhanna Emanuela Fontenele Lima de Carvalho, Adriano Max Moreira Reis, Leila Márcia Pereira de Faria, Karine Santana de Azevedo Zago, Silvia Helena De Bortoli Cassiani, Prevalence of drug interactions in intensive care units in Brazil, Acta Paul Enferm. 2013; 26(2):150-7. Martína M, Codinna C, Tuseta M, Carné X, Noguéc, S, Ribasa J. Problemas relacionados con la medicación como causa del ingreso hospitalario, Med Clin (Barc) 2002;118(6):205-10 Pirmohamed M., James S., Meakin S., Green C., Scout A., Walley T., Farrar K., Park K., Breckenridge A. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18.820 patients. BMJ 2004; 329:15-19 Pouyanne P., Haramburu F., Imbs J., Bégaud B. Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. BMJ 2000; 320: 1036 A. David Rodríguez, Drug- drug interactions, drugs and the pharmaceutical sciences, 2th Ed, Vol 179, (2008); p. 643-659 R. A. Caribé, G. R. Chaves, J. D. Pocognoni2 e I. A. Souza, Potenciales interacciones medicamentosas en pacientes con sepsis internados en la unidad de terapia intensiva, Farm Hosp. 2013;37(5):383-387 Rivkin A, Yin H. Evaluation of the role of the critical care pharmacist in identifying and avoiding or minimizing significant drug-drug interactions in medical intensive care patients. J Crit Care. 2011 Feb;26(1):104.e1-e6. Reis AM, De Bortoli Cassiani SH. Prevalence of potential drug interactions in patients in an intensive care unit of a university hospital in Brazil Clinics 2011; 66: 9–15. Plaza J, Álamo M, Torres P, Fuentes A, López F, Interacciones de medicamentos y eventos adversos en fármacos utilizados en una unidad de cuidados intensivos, Rev Med Chile 2010; 138: 452-460 Bergk V, Gasse C, Rothenbacher D, Loew M, Brenner H, Haefeli WE. Drug interactions in primary care: impact of a new algorithm on risk determination. Clin Pharmacol Ther 2004; 76: 85-96 Marjan Askari, Saied Eslami, Mathijs Louws, Peter C. Wierenga, Dave A. Dongelmans, Rob A. Kuiper and Ameen Abu-Hanna, Frequency and nature of drugdrug interactions in the intensive care unit, Pharmacoepidemiology and Drug Safety, 2013; 22: 430–437 Smithburger P, Kane-Gill SL, Seybert AL, Drug–drug interactions in the medical intensive care unit: an assessment of frequency, severity and the medications involved, International Journal of Pharmacy Practice 2012, 20, pp. 402–408 Committee on Quality of Health Care in America: Institute of Medicine. To erris human: building a safer health system. Washington, DC: National Academy Press; 2000 Silvana Maria de Almeida1, Cinthia Scatena Gama, Nelson Akamine, Prevalence and classification of drug-drug interactions in intensive care patients, Einstein. 2007; 5(4):347-351 E. Sona, M.L Gora, y S.L Roeder; Methods used by pharmacy departments to identify drugs interactions, Am. J Hosp. Pharm., 50, 2546 (1993) Grattagliano I, Portincasa P, D´Ambrosio G, Palmieri VO, Palaciano G. Avoiding drug interactions: here´s help. J Fam Pract 2010;59:322-9. Strand LM, Morley PC, Cipolle RJ, Ramsey R, Lamsam GD. Drug-related problems: their structure and function. Drug Intell Clin Pharm 1990; 24: 1093-7. Bucşa Camelia, Farcaş Andreea, Cazacu Irina, Leucuta Daniel, Achimas-Cadariu Andrei, Mogosan Cristina, Bojita Marius, How many potential drug–drug interactions cause adverse drug reactions in hospitalized patients?, European Journal of Internal Medicine 24 (2013) 27–33. Hammes J, Pfuetzenreiter F, da Silveira F, Koenig A, Adrieno Westphal G, Potential drug interactions prevalence in intensive care units Rev Bras Ter Intensiva. 2008; 20(4): 349-354 Becker et al, Hospitalizations and emergency department visits due to drug–drug interactions: a literature review, Pharmacoepidemiology and Drug Safety, 2007; 16: 641–651 Medscape Multispeciality, Identification and Management of Drug Interactions, Faculty and Disclosures. http://www.medscape.org/viewarticle/41837 J. Díaz, J. López, Descripción de las Interacciones fármaco-fármaco en los servicios de Medicina interna de tres hospitales de tercer nivel de Bogotá, Rev. Col. Cienc. Quím. Farm. 34 (2), 181-192, Vol. 34, No. 2, 2005. Joseph A. Khan A. A comparison of the Micromedex and Lexicomp medicine information databases, BHR Hospitals Sept 2004, http://www.ukmi.nhs.uk/filestore/misc/AcomparisonoftheMicromedexandLexicompDatabases.pdf Barrons R. Evaluation of personal digital assistant software for drug interactions. Am J Health Syst Pharm. 2004; 61(4):380-85. Roberts D, Richard H. Drug absorption, distribution, metabolism and excretion considerations in critically ill adults. Expert Opin, Drug Metab. Toxicol. (2013) 9(9). Hansten, P.D. Drug Interaction management. Pharm. World Sci 2003; 25 (3):94- 97, doi: 10.1023/A: 1024077018902. Doubova SV, Reyes-Morales H, del Pilar Torres-Arreola L, Suárez-Ortega M. Potential drug - drug and drug– disease interactions in prescriptions for ambulatory patients over 50 years of age in family medicine clinics in Mexico City. BMC Health Serv Res 2007; 7:147. Zhan C, Coreea de Araujo R, Bierman AS, Sangl J, Miller MR, Wickizer SW, et al. Suboptimal prescribing in elderly outpatients: potentially harmful drug –drug and drug – disease combinations. J Am Geriatr Soc 2005;53:262-7 Devlin JW, Roberts RJ. Pharmacology of commonly used analgesics and sedatives in the ICU: benzodiazepines, propofol, and opioids. Crit Care Clin. 2009;25:431-49, doi: 10.1016/j.ccc.2009.03.003 Riker RR, Fraser GL. Altering intensive care sedation paradigms to improve patient outcomes. Crit Care Clin. 2009; 25:527-38. Chweickert WD, Kress JP. Strategies to optimize analgesia and sedation. Crit Care. 2008; 12 Suppl 3:S6 Overholser BR, Foster DR. Opioid pharmacokinetic drug-drug interactions. Am J Manag Care. 2011 Sep; 17 Suppl 11:S276-87. Review. López M, Metabolismo de fármacos: Enzimas CYP3A (sub familia del citocromo P450), 20 mar. 2013 14:22 infofarmacia www.infofarmacia.com/bioquimica/metabolismo-de-farmacos-enzimas-cyp3a-sub-familia-delcitocromo-p450 Wolters Kluwer Health Lexicomp, comprehensive pharmacology information app. 2015 Cruciol-Souza JM, Thomson JC. Prevalence of potential drug-drug interactions and its associated factors in a Brazilian teaching hospital. J Pharm Pharm Sci. 2006; 9:427-33. Lima REF, Cassiani SHB. Potential drug interactions in intensive care patients at a teaching hospital. Rev Latinoam Enfermagem 2009 março-abril; 17(2):222-7. El Samia Mohamed SMA, Gad ZM, El-Nimr NA, Abdel Razek AAH (2013) Prevalence and Pattern of Potential Drug-Drug Interactions in the Critical Care Units of a Tertiary Hospital in Alexandria, Egypt. Adv Pharmacoepidemiol Drug Saf 2: 144. 261219 TE07725
url	http://hdl.handle.net/10818/17940
dc.language.iso.es_CO.fl_str_mv	spa
language	spa
dc.rights.*.fl_str_mv	Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.coar.fl_str_mv	http://purl.org/coar/access_right/c_abf2
dc.rights.uri.*.fl_str_mv	http://creativecommons.org/licenses/by-nc-nd/4.0/
rights_invalid_str_mv	Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ http://purl.org/coar/access_right/c_abf2
dc.publisher.none.fl_str_mv	Universidad de La Sabana
dc.publisher.program.es_CO.fl_str_mv	Especialización en Farmacología Clínica
dc.publisher.department.es_CO.fl_str_mv	Facultad de Medicina
publisher.none.fl_str_mv	Universidad de La Sabana
dc.source.none.fl_str_mv	Universidad de La Sabana Intellectum Repositorio Universidad de La Sabana
institution	Universidad de la Sabana
bitstream.url.fl_str_mv	https://intellectum.unisabana.edu.co/bitstream/10818/17940/4/Marcela%20Hern%c3%a1ndez%20Londo%c3%b1o%20%28tesis%29.pdf.txt https://intellectum.unisabana.edu.co/bitstream/10818/17940/1/Marcela%20Hern%c3%a1ndez%20Londo%c3%b1o%20%28tesis%29.pdf https://intellectum.unisabana.edu.co/bitstream/10818/17940/2/license_rdf https://intellectum.unisabana.edu.co/bitstream/10818/17940/3/license.txt https://intellectum.unisabana.edu.co/bitstream/10818/17940/5/Marcela%20Hern%c3%a1ndez%20Londo%c3%b1o%20%28Carta%29.pdf
bitstream.checksum.fl_str_mv	93772f6d976cc89f7c8a04c4fafe1124 6735a4f6d9bea47cd355ab6a593b708a 7c9ab7f006165862d8ce9ac5eac01552 f52a2cfd4df262e08e9b300d62c85cab bbf77d2858348abe3681919cb98a23a4
bitstream.checksumAlgorithm.fl_str_mv	MD5 MD5 MD5 MD5 MD5
repository.name.fl_str_mv	Intellectum Universidad de la Sabana
repository.mail.fl_str_mv	contactointellectum@unisabana.edu.co
_version_	1811952253211246592
spelling	Bustamante Rojas, Carlos EduardoTribiño, GabrielHernández Londoño, MarcelaEspecialista en Farmacología Clínica2015-08-27T16:41:37Z2015-08-27T16:41:37Z2015-08-212015-08-2120152015-08-27Rhanna Emanuela Fontenele Lima de Carvalho, Adriano Max Moreira Reis, Leila Márcia Pereira de Faria, Karine Santana de Azevedo Zago, Silvia Helena De Bortoli Cassiani, Prevalence of drug interactions in intensive care units in Brazil, Acta Paul Enferm. 2013; 26(2):150-7.Martína M, Codinna C, Tuseta M, Carné X, Noguéc, S, Ribasa J. Problemas relacionados con la medicación como causa del ingreso hospitalario, Med Clin (Barc) 2002;118(6):205-10Pirmohamed M., James S., Meakin S., Green C., Scout A., Walley T., Farrar K., Park K., Breckenridge A. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18.820 patients. BMJ 2004; 329:15-19Pouyanne P., Haramburu F., Imbs J., Bégaud B. Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. BMJ 2000; 320: 1036A. David Rodríguez, Drug- drug interactions, drugs and the pharmaceutical sciences, 2th Ed, Vol 179, (2008); p. 643-659R. A. Caribé, G. R. Chaves, J. D. Pocognoni2 e I. A. Souza, Potenciales interacciones medicamentosas en pacientes con sepsis internados en la unidad de terapia intensiva, Farm Hosp. 2013;37(5):383-387Rivkin A, Yin H. Evaluation of the role of the critical care pharmacist in identifying and avoiding or minimizing significant drug-drug interactions in medical intensive care patients. J Crit Care. 2011 Feb;26(1):104.e1-e6.Reis AM, De Bortoli Cassiani SH. Prevalence of potential drug interactions in patients in an intensive care unit of a university hospital in Brazil Clinics 2011; 66: 9–15.Plaza J, Álamo M, Torres P, Fuentes A, López F, Interacciones de medicamentos y eventos adversos en fármacos utilizados en una unidad de cuidados intensivos, Rev Med Chile 2010; 138: 452-460Bergk V, Gasse C, Rothenbacher D, Loew M, Brenner H, Haefeli WE. Drug interactions in primary care: impact of a new algorithm on risk determination. Clin Pharmacol Ther 2004; 76: 85-96Marjan Askari, Saied Eslami, Mathijs Louws, Peter C. Wierenga, Dave A. Dongelmans, Rob A. Kuiper and Ameen Abu-Hanna, Frequency and nature of drugdrug interactions in the intensive care unit, Pharmacoepidemiology and Drug Safety, 2013; 22: 430–437Smithburger P, Kane-Gill SL, Seybert AL, Drug–drug interactions in the medical intensive care unit: an assessment of frequency, severity and the medications involved, International Journal of Pharmacy Practice 2012, 20, pp. 402–408Committee on Quality of Health Care in America: Institute of Medicine. To erris human: building a safer health system. Washington, DC: National Academy Press; 2000Silvana Maria de Almeida1, Cinthia Scatena Gama, Nelson Akamine, Prevalence and classification of drug-drug interactions in intensive care patients, Einstein. 2007; 5(4):347-351E. Sona, M.L Gora, y S.L Roeder; Methods used by pharmacy departments to identify drugs interactions, Am. J Hosp. Pharm., 50, 2546 (1993)Grattagliano I, Portincasa P, D´Ambrosio G, Palmieri VO, Palaciano G. Avoiding drug interactions: here´s help. J Fam Pract 2010;59:322-9.Strand LM, Morley PC, Cipolle RJ, Ramsey R, Lamsam GD. Drug-related problems: their structure and function. Drug Intell Clin Pharm 1990; 24: 1093-7.Bucşa Camelia, Farcaş Andreea, Cazacu Irina, Leucuta Daniel, Achimas-Cadariu Andrei, Mogosan Cristina, Bojita Marius, How many potential drug–drug interactions cause adverse drug reactions in hospitalized patients?, European Journal of Internal Medicine 24 (2013) 27–33.Hammes J, Pfuetzenreiter F, da Silveira F, Koenig A, Adrieno Westphal G, Potential drug interactions prevalence in intensive care units Rev Bras Ter Intensiva. 2008; 20(4): 349-354Becker et al, Hospitalizations and emergency department visits due to drug–drug interactions: a literature review, Pharmacoepidemiology and Drug Safety, 2007; 16: 641–651Medscape Multispeciality, Identification and Management of Drug Interactions, Faculty and Disclosures. http://www.medscape.org/viewarticle/41837J. Díaz, J. López, Descripción de las Interacciones fármaco-fármaco en los servicios de Medicina interna de tres hospitales de tercer nivel de Bogotá, Rev. Col. Cienc. Quím. Farm. 34 (2), 181-192, Vol. 34, No. 2, 2005.Joseph A. Khan A. A comparison of the Micromedex and Lexicomp medicine information databases, BHR Hospitals Sept 2004, http://www.ukmi.nhs.uk/filestore/misc/AcomparisonoftheMicromedexandLexicompDatabases.pdfBarrons R. Evaluation of personal digital assistant software for drug interactions. Am J Health Syst Pharm. 2004; 61(4):380-85.Roberts D, Richard H. Drug absorption, distribution, metabolism and excretion considerations in critically ill adults. Expert Opin, Drug Metab. Toxicol. (2013) 9(9).Hansten, P.D. Drug Interaction management. Pharm. World Sci 2003; 25 (3):94- 97, doi: 10.1023/A: 1024077018902.Doubova SV, Reyes-Morales H, del Pilar Torres-Arreola L, Suárez-Ortega M. Potential drug - drug and drug– disease interactions in prescriptions for ambulatory patients over 50 years of age in family medicine clinics in Mexico City. BMC Health Serv Res 2007; 7:147.Zhan C, Coreea de Araujo R, Bierman AS, Sangl J, Miller MR, Wickizer SW, et al. Suboptimal prescribing in elderly outpatients: potentially harmful drug –drug and drug – disease combinations. J Am Geriatr Soc 2005;53:262-7Devlin JW, Roberts RJ. Pharmacology of commonly used analgesics and sedatives in the ICU: benzodiazepines, propofol, and opioids. Crit Care Clin. 2009;25:431-49, doi: 10.1016/j.ccc.2009.03.003Riker RR, Fraser GL. Altering intensive care sedation paradigms to improve patient outcomes. Crit Care Clin. 2009; 25:527-38.Chweickert WD, Kress JP. Strategies to optimize analgesia and sedation. Crit Care. 2008; 12 Suppl 3:S6Overholser BR, Foster DR. Opioid pharmacokinetic drug-drug interactions. Am J Manag Care. 2011 Sep; 17 Suppl 11:S276-87. Review.López M, Metabolismo de fármacos: Enzimas CYP3A (sub familia del citocromo P450), 20 mar. 2013 14:22 infofarmacia www.infofarmacia.com/bioquimica/metabolismo-de-farmacos-enzimas-cyp3a-sub-familia-delcitocromo-p450Wolters Kluwer Health Lexicomp, comprehensive pharmacology information app. 2015Cruciol-Souza JM, Thomson JC. Prevalence of potential drug-drug interactions and its associated factors in a Brazilian teaching hospital. J Pharm Pharm Sci. 2006; 9:427-33.Lima REF, Cassiani SHB. Potential drug interactions in intensive care patients at a teaching hospital. Rev Latinoam Enfermagem 2009 março-abril; 17(2):222-7.El Samia Mohamed SMA, Gad ZM, El-Nimr NA, Abdel Razek AAH (2013) Prevalence and Pattern of Potential Drug-Drug Interactions in the Critical Care Units of a Tertiary Hospital in Alexandria, Egypt. Adv Pharmacoepidemiol Drug Saf 2: 144.Strand LM, Morley PC, Cipolle RJ, Ramsey R, Lamsam GD. Drug-related problems: their structure and function. Drug Intell Clin Pharm 1990; 24: 1093-7.http://hdl.handle.net/10818/17940261219TE0772544 Páginas incluye diagramasObjetivos - Identificar y caracterizar las potenciales interacciones fármaco- fármaco provenientes de la prescripción generada durante la estancia hospitalaria en una Unidad de Cuidado Intensivo y evaluar factores asociados a su génesis. Métodos: Se ensambló una cohorte retrospectiva a partir de los pacientes hospitalizados en la UCI de una clínica privada entre junio 1 y diciembre 31 de 2013. Se evaluó la prescripción diaria de cada paciente, obtenida a partir de la base de datos de la clínica, en busca de potenciales interacciones farmacológicas mediante el programa Lexicomp. Se calculó la incidencia de interacciones, se determinó su clasificación según tipo, severidad, tiempo de aparición y nivel de documentación, y se evaluaron factores asociados a su génesis mediante regresión logística. Resultados Se encontró una proporción de pacientes con al menos una interacción de 84% (263/312) con una densidad de incidencia de 5,8 x 10 persona – día de estancia en UCI, la proporción de pacientes con más de una interacción fue de 87%, la mediana del número de interacciones fue de 6 por paciente con una tasa absoluta de 7,07 interacciones/ día, la interacción más frecuente fue fentanilo + midazolam con un 23%, las más frecuentes según severidad fueron las moderadas con 77,6% y según documentación fueron las moderadas con 52,6%. El fármaco índice más frecuente fue midazolam con el 12% y el precipitante fue el fentanilo con 10,6%. La edad y el número de medicamentos se asociaron con la generación de interacciones (OR=3,1 y OR= 11,83 respectivamente).spaUniversidad de La SabanaEspecialización en Farmacología ClínicaFacultad de MedicinaAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/http://purl.org/coar/access_right/c_abf2Universidad de La SabanaIntellectum Repositorio Universidad de La SabanaMedicamentos -- ColombiaAdministración -- Cuidados intensivosAtención médicaCaracterización de las potenciales interacciones fármaco-fármaco en pacientes hospitalizados en una unidad de cuidados intensivos de un hospital de tercer nivel.bachelorThesisTesis de especializaciónpublishedVersionhttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_7a1fTEXTMarcela Hernández Londoño (tesis).pdf.txtMarcela Hernández Londoño (tesis).pdf.txtExtracted Texttext/plain45https://intellectum.unisabana.edu.co/bitstream/10818/17940/4/Marcela%20Hern%c3%a1ndez%20Londo%c3%b1o%20%28tesis%29.pdf.txt93772f6d976cc89f7c8a04c4fafe1124MD54ORIGINALMarcela Hernández Londoño (tesis).pdfMarcela Hernández Londoño (tesis).pdfVer documento en PDFapplication/pdf582800https://intellectum.unisabana.edu.co/bitstream/10818/17940/1/Marcela%20Hern%c3%a1ndez%20Londo%c3%b1o%20%28tesis%29.pdf6735a4f6d9bea47cd355ab6a593b708aMD51CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-81223https://intellectum.unisabana.edu.co/bitstream/10818/17940/2/license_rdf7c9ab7f006165862d8ce9ac5eac01552MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-8498https://intellectum.unisabana.edu.co/bitstream/10818/17940/3/license.txtf52a2cfd4df262e08e9b300d62c85cabMD53Marcela Hernández Londoño (Carta).pdfMarcela Hernández Londoño (Carta).pdfapplication/pdf374001https://intellectum.unisabana.edu.co/bitstream/10818/17940/5/Marcela%20Hern%c3%a1ndez%20Londo%c3%b1o%20%28Carta%29.pdfbbf77d2858348abe3681919cb98a23a4MD5510818/17940oai:intellectum.unisabana.edu.co:10818/179402020-03-31 16:25:03.884Intellectum Universidad de la Sabanacontactointellectum@unisabana.edu.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

Caracterización de las potenciales interacciones fármaco-fármaco en pacientes hospitalizados en una unidad de cuidados intensivos de un hospital de tercer nivel.

Publicaciones similares